...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage
【24h】

A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage

机译:PSD-95的高亲和力,二聚体抑制剂与PDZ1-2双价相互作用,并防止缺血性脑损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-D-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)_2 (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-di-mer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.
机译:抑制突触支架蛋白突触后密度蛋白95(PSD-95),神经元一氧化氮合酶(nNOS)和N-甲基-D-天门冬氨酸(NMDA)受体的三元蛋白复合物是治疗缺血性疾病的潜在策略脑损伤,但缺乏高亲和力抑制剂。在这里,我们报告设计和合成的新型二聚体抑制剂,Tat-NPEG4(IETDV)_2(Tat-N-二聚体),其以4.6nM的前所未有的高亲和力结合PSD-95的串联PDZ1-2域,并且通过在人血浆中的稳定性测量在体外评估显示出广泛的蛋白酶抗性。 X射线晶体学,NMR和小角X射线散射(SAXS)推论出二聚抑制剂与PDZ1-2之间真正的二价相互作用,并且还提供了由二聚抑制剂诱导的PDZ1-2构象变化的动力学模型。 。向遭受局灶性脑缺血的小鼠单次静脉注射Tat-N-di-mer(3 nmol / g)可以减少40%的梗塞体积并恢复运动功能。因此,Tat-N-二聚体是一种中风具有治疗潜力的高效神经保护剂。

著录项

  • 来源
  • 作者单位

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, SE-75123 Uppsala, Sweden;

    European Molecular Biology Laboratory, Grenoble Outstation, 38042 Grenoble, France;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, SE-75123 Uppsala, Sweden;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

    Department of Physics, Chemistry and Biology, Division of Molecular Biotechnology, Linkoping University, SE-58183, Linkoping, Sweden;

    Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense, Denmark;

    Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    drug discovery; ischemic stroke; protein-protein interactions;

    机译:药物发现;缺血性中风;蛋白质相互作用;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号